GlassScriptPhysician profile
Emily Anne Quick
NPI 1457034704
$1,221.08
in general payments reported to CMS, 2019-2025
19 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $46.53 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $232.08 | 2025 | |
| Calliditas Therapeutics US INC. | $167.35 | 2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $94.07 | 2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $90.24 | 2025 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $88.45 | 2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $80.73 | 2025 | |
| Amgen INC. | $63.21 | 2025 | Krystexxa, Tavneos |
| Ardelyx, INC. | $55.68 | 2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.75 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.64 | 2025 | |
| Lilly USA, LLC | $42.24 | 2025 | Jardiance, Zepbound |
| Sobi, INC | $41.28 | 2025 | |
| Alexion Pharmaceuticals, INC. | $31.83 | 2025 | Ultomiris |
| Pfizer INC. | $30.33 | 2023 | |
| Boston Scientific Corporation | $27.27 | 2025 | Watchman |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.32 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $20.88 | 2025 | Benlysta |
| Scpharmaceuticals INC. | $17.53 | 2025 | |
| Novo Nordisk INC | $16.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.